Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity

— NKTR-358 Elicited Sustained and Preferential Proliferation of Regulatory T Cells Without Corresponding Effects on T Effector Cells in Preclinical Models, Supporting Development in a Broad Range of Autoimmune Disorders — SAN FRANCISCO , May 20, 2021 /PRNewswire/ —  Nektar Therapeutics  (Nasdaq:


Get every new post delivered right to your inbox.

Original Source